Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report)’s stock price was up 13.9% during trading on Monday . The stock traded as high as $0.32 and last traded at $0.32. Approximately 2,175 shares were traded during trading, a decline of 45% from the average session volume of 3,966 shares. The stock had previously closed at $0.2809.
Relief Therapeutics Price Performance
The firm’s 50-day simple moving average is $0.27 and its 200-day simple moving average is $0.55.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical?stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF?100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Recommended Stories
- Five stocks we like better than Relief Therapeutics
- Speed Sells: Cerebras Cracks the Silicon Ceiling
- Amid Legal Risks, This Company Is Still Rated a Buy
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
